Shingrix Injection, Solution
NDC Package 50090-7919-0
Package Information
Shingrix (zoster vaccine recombinant, adjuvanted) injection is this vaccine is used by adults 50 years and older to prevent zoster (shingles). This formulation utilizes a injection, solution delivery system. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-7919 and is authorized under FDA application BLA125614.
Identification & Billing
- RxCUI: 2719774 - varicella zoster virus glycoprotein E, recombinant vaccine 0.5 ML Prefilled Syringe
- RxCUI: 2719774 - 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Prefilled Syringe
- RxCUI: 2719778 - SHINGRIX vaccine 0.5 ML Prefilled Syringe
- RxCUI: 2719778 - 0.5 ML varicella zoster virus glycoprotein E, recombinant 0.1 MG/ML Prefilled Syringe [Shingrix]
- RxCUI: 2719778 - 0.5 ML Shingrix 0.1 MG/ML Prefilled Syringe
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50090 - A-s Medication Solutions
- 50090-7919 - Shingrix
- 50090-7919-0 - 1 mL in 1 KIT
- 50090-7919 - Shingrix
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50090-7919-0 identifies a specific commercial package of 1 ml in 1 kit of Shingrix, a vaccine label labeled by A-s Medication Solutions. This product is billed per "ML" milliliter and contains an estimated amount of 1 billable units per package. This injection, solution is formulated for intramuscular use and contains recombinant varicella zoster virus glycoprotein e antigen as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by A-s Medication Solutions on July 16, 2025. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This vaccine is used by adults 50 years and older to prevent zoster (shingles). Zoster is caused by the same virus that causes chickenpox. After you have been infected with chickenpox (usually in childhood), the virus can live in your body's nerve roots in an inactive form. For reasons that are not fully understood, the virus may become active again. This causes shingles with symptoms of rash, blisters, and pain. This vaccine works by boosting the body's natural defense (immunity) against the zoster virus so that symptoms of shingles do not develop. It should not be used for treating active shingles, nerve pain caused by shingles, or for the prevention of chickenpox. Vaccines may not fully protect everyone who receives them. This vaccine should not be used by children.
How is this A-s Medication Solutions product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090791900. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.
